


Product Name : Senexin-A
Cat. No. : PC-44628
CAS No. : 1366002-50-7
Molecular Formula : C₁₇H₁₄N₄
Molecular Weight : 274.32
Target : Cyclin-dependent Kinase (CDK)
Solubility : DMSO: ≥100 mg/mL



Biological Activity

Senexin-A is a selective inhibitor of **CDK8** (IC₅₀=0.28 μM) and **CDK19**, inhibits CDK8 and CDK19 ATP site binding with K_d50 of 0.83 μM and 0.31 μM, respectively.

Senexin-A inhibits only p21-induced transcription but not other biological effects of p21, inhibits β-catenin-dependent transcription in HCT116 colon carcinoma cells.

Senexin-A suppresses damage-induced tumor-promoting paracrine activities of tumor cells and normal fibroblasts.

Senexin-A reverses the increase in tumor engraftment and serum mitogenic activity in mice pretreated with doxorubicin.

References

Porter DC, et al. *Proc Natl Acad Sci U S A*. 2012 Aug 21;109(34):13799-804.

McDermott MS, et al. *Oncotarget*. 2017 Feb 21;8(8):12558-12575.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com